The Repurposing of Old Drugs or Unsuccessful Lead Compounds by in Silico Approaches: New Advances and Perspectives

Current Topics in Medicinal Chemistry

Volumn 16, Issue 19, 2016, Pages 2088-2106

  Martorana, Annamaria ^a   Perricone, Ugo ^a   Lauria, Antonino ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Drug design; Drug repositioning; Drug repurposing; In silico approaches; Lead compound; Ligand based; Structure Based

Indexed keywords

LEAD; LIGAND; MINOXIDIL; RALOXIFENE; SILDENAFIL; THALIDOMIDE;

ARTICLE; COMPUTER MODEL; COMPUTER PROGRAM; DATA MINING; DRUG CYTOTOXICITY; DRUG DATABASE; DRUG DESIGN; DRUG EFFICACY; DRUG REPOSITIONING; DRUG SAFETY; DRUG TARGETING; EC50; GENE EXPRESSION; HUMAN; IC50; MEDICINAL CHEMISTRY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); QUANTITATIVE STRUCTURE ACTIVITY RELATION; COMPUTER SIMULATION; FACTUAL DATABASE; MOLECULAR MODEL; PROCEDURES; SOFTWARE;

CHEMISTRY, PHARMACEUTICAL; COMPUTER SIMULATION; DATABASES, FACTUAL; DRUG DESIGN; DRUG REPOSITIONING; HUMANS; LIGANDS; MODELS, MOLECULAR; SOFTWARE;

EID: 84975780232     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026616666160216153457     Document Type: Article

References (165)

1. Pammolli, F.; Magazzini, L.; Riccaboni, M. The productivity crisis in pharmaceutical R and D. Nat. Rev. Drug Discov., 2011, 10, 428-438.
2. Stephens, T.D.; Brynner, R. Dark remedy: The impact of thalidomide and its revival as a vital medicine, 1st ed.; Basic Books: New York, 2001.
3. Sheskin, J. Thalidomide in lepra reaction. Int. J..Dermatol., 1975, 14(8), 575-576.
4. D’Amato, R.J.; Loughnan, M.S.; Flynn, E.; Folkman, J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA, 1994, 91, 4082-4085.
5. Singhal, S.; Mehta, J.; Desikan, R.; Ayers, D.; Roberson, P.; Eddlemon, P.; Munshi, N.; Anaissie, E.; Wilson, C.; Dhodapkar, M.; Zeddis, J.; Barlogie, B. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med., 1999, 341, 1565-1571.
6. Ning, Y.M.; Gulley, J.L.; Arlen, P.M.; Woo, S.; Steinberg, S.M.; Wright, J.J.; Parnes, H.L.; Trepel, J.B.; Lee, M.J.; Kim, Y.S.; Sun, H, Madan RA, Latham L, Jones E, Chen CC, Figg WD, Dahut W.L. Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J. Clin. Oncol., 2010, 28, 2070-2076.
7. Jordan, V.C.; Phelps, E.; Lindgren, J.U. Effects of anti-estrogens on bone in castrated and intact female rats. Breast cancer Res. Treat., 1987, 10(1), 31-35.
8. Ashburn, T.T.; Thor, K.B. Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov., 2004, 3(8), 673-683.
9. FDA Raloxifene hydrochloride. http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm129243.htm. (Accessed September, 2007).
10. Boolell, M.; Allen, M.J.; Ballard, S.A.; Gepi-Attee, S.; Muirhead, G.J.; Naylor, A.M.; Naylor, A.M.; Osterloh, I.H.; Gingell, C. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int. J. Impot. Res., 1996, 8, 47-52.
11. Joekes, A.M.; Thompson, F.D.; O’Regan, P.F. Clinical use of minoxidil (Loniten). J. R. Soc. Med., 1981, 74(4), 278-282.
12. Olsen, E.A.; Whiting, D.; Bergfeld, W.; Miller, J.; Hordinsky, M.; Wanser, R.; Zhang, P.; Kohut, B. A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. J. Am. Acad. Dermatol., 2007, 57(5), 767-774.
13. Stone, J.E.; Phillips, J.C.; Freddolino, P.L.; Hardy D.J.; Trabuco, L.G.; Schulten, K. Accelerating molecular modeling applications with graphics processors, J. Comput. Chem., 2007, 28 (16), 2618-2640.
14. Stone, J. E.; Hardy, D. J.; Ufimtsev, I. S.; Schulten, K. GPUaccelerated molecular modeling coming of age, J. Mol. Graph. Model., 2010, 29(2), 116-125.
15. Dudley, J.T.; Desphande, T.; Butte, A.J. Exploiting drug-disease relationships for computational drug repositioning, Brief Bioinform., 2011, 12(4), 303-311.
16. Waldman, S.A.; Terzic, A. Systems-Based Discovery Advances Drug Development, Clin. Pharmacol. Ther., 2013, 93(4), 285-287.
17. Gaulton, A.; Overington, J.P. Role of open chemical data in aiding drug discovery and design, Fut. Med. Chem., 2010, 2, 903-907.
18. Azencott, C. A.; Ksikes, A.; Swamidass, S.J.; Chen, J. H.; Ralaivola, L.; Baldi, P. One-to four-dimensional kernels for virtual screening and the prediction of physical, chemical, and biological properties, J. Chem. Inf. Model., 2007, 47, 965-974.
19. Cheng, F.; Sutariya, V. Applications of Artificial Neural Network Modeling in Drug Discovery, Clin. Exp. Pharmacol., 2012, 2(3), 113-116.
20. Siegel, M.G.; Vieth, M. Drugs in other drugs: a new look at drugs as fragments, Drug Discov. Today, 2007, 2, 71-79.
21. Millera, J.R.; Dunhama, S.; Mochalkina, I.; Banotaia, C.; Bowmana, M; Buista, S; Dunklea, B; Hannaa, D; Harwoodb, H.J.; Hubanda, M.D; Karnovskya, A; Kuhna, M.; Limberakisa, C; Liua, J.Y; Mehrensa, S.; Muellera, T.S; Narasimhana, L.; Ogdena, A.; Ohrena, J.; Vara Prasada, J.V.N.; Shellya, J.A.; Skerlosa, L.; Sulavika, M.; Thomasa, V.H.; VanderRoesta, S.; Wangc, L.; Wanga, Z.; Whittona, A; Zhua, T; Stovera, C.K. A class of selective antibacterials derived from a protein kinase inhibitor pharmacophore. P. Natl. Acad. Sci. USA, 2009, 106, 1737-1742.
22. Walsh, C.T.; Fischbach, M.A. Repurposing libraries of eukaryotic protein kinase inhibitors for antibiotic discovery, P. Natl. Acad. Sci. USA, 2009, 106, 1689-1690.
23. Young, D.W; Bender, A.; Hoyt, J.; McWhinnie, E.; Chirn, G.W.; Tao C.Y.; Tallarico J.A.; Labow M.; Jenkins J.L.; Mitchison T.J.; Feng Y. Integrating high-content screening and ligand-target prediction to identify mechanism of action, Nat. Chem. Biol., 2008, 4(1), 59-68.
24. Keiser, M.J.; Setola, V.; Irwin, J.J.; Laggner C.; Abbas, A.I.; Hufeisen, S.J.; Jensen, N.H.; Kuijer, M.B.; Matos, R.C.; Tran, T.B.; Whaley, R.; Glennon, R.A.; Hert J.; Thomas, K.L.H.; Edwards, D.D.; Shoichet, B.K.; Roth, B.L. Predicting new molecular targets for known drugs, Nature, 2009, 462, 175-181.
25. Bender, A.; Jenkins, J.L.; Glick, M.; Deng, Z.; Nettles, J.H.; Davies, J.W. Bayes affinity fingerprints improve retrieval rates in virtual screening and define orthogonal bioactivity space: when are multitarget drugs a feasible concept?, J. Chem. Inf. Model., 2006, 46, 2445-2456.
26. Rognan, D. Structure-based approaches to target fishing and ligand profiling, Mol. Inf., 2010, 29(3), 176-187.
27. Teo, C.Y.; Abdul Rahman, M.B.; Thean Chor A.L.; Salleh A.B.; Ballester P.J.; Tejo B.A. Ligand-Based Virtual Screening for the Discovery of Inhibitors for Protein Arginine Deiminase Type 4 (PAD4), Metabolomics, 2013, 3, 118-122.
28. Swamidass, S.J. Mining small-molecule screens to repurpose drugs, Brief Bioinform., 2011, 12(4), 327-35.
29. Wang, Y.; Chen, S.; Deng, N. Drug repositioning by kernel-based integration of molecular structure, molecular activity, and phenotype data, PLoS One, 2013, 8(11), e78518.
30. Desaphy, J.; Raimbaud, E.; Ducrot, P.; Rognan D. Encoding protein-ligand interaction patterns in fingerprints and graphs J. Chem. Inf. Model., 2013, 53(3), 623-637.
31. Tan, F.J.; Yang, R.Z.; Xu X.X.; Chen, X.; Wang, Y.; Ma, H.; Liu, X.; Wu, X.; Chen, Y.; Liu, L.; Jia, X. Drug repositioning by applying ‘expression profiles’ generated by integrating chemical structure similarity and gene semantic similarity, Mol. Biosyst., 2014, 10(5), 1126-38.
32. Ng, C.; Hauptman, R.; Zhang, Y.; Bourne, P.E.; Xie, L. Antiinfectious drug repurposing using an integrated chemical genomics and structural systems biology approach, Pac. Symp. Biocomput., 2014, 136-47.
33. Lee, M.; Kim, D. Large-scale reverse docking profiles and their applications, BMC Bioinfo., 2012, 13(17), S6, 1-10.
34. Grinter, S.Z. Liang, Y.; Huang, S.Y.; Hyder, S.M.; Zou, X. An inverse docking approach for identifying new potential anti-cancer targets, J. Mol. Graph. Model., 2011, 29, 795-799.
35. Henrik, K.; Feng, Z; Bluhm, W.F.; Dimitropoulos, D.; Doreleijers, J.F.; Dutta, S.; Flippen-Anderson, J.L.; Ionides, J.; Kamada, C.; Krissinel, E.; Lawson, C.L.; Markley, J.L.; Nakamura, H.; Newman, R.; Shimizu, Y.; Swaminathan, J; Velankar, S.; Ory, J.; Ulrich E.L.; Vranken, W.; Westbrook, J.; Yamashita, R.; Yang, H.; Young, J.; Yousufuddin, M.; Berman, H.M.; Remediation of the Protein Data Bank archive, Nuc. Acids Res., 2008, 36, D426-D433.
36. Langer, T. Pharmacophores in drug research, Mol. Info., 2010, 29(6-7), 470-475.
37. Duwensee, K.; Schwaiger, S.; Tancevski, I.; Eller, K.; Van Eck, M.; Markt, P.; Linder, T.; Stanzl, U.; Ritsch, A.; Patsch, J.R.; Schuster, D.; Stuppner, H.; Bernhard, D.; Eller, P. Leoligin, the major lignan from Edelweiss, activates cholesteryl ester transfer protein, Atherosclerosis, 2011, 219, 109-115.
38. Nashev, L.G.; Vuorinen, A.; Praxmarer, L.; Chantong, B.; Cereghetti, D.; Winiger, R.; Schuster, D.; Odermatt, A. Virtual screening as a strategy for the identification of xenobiotics disrupting corticosteroid action, Plos One, 2012, 7(10), e46958.
39. Haupt, V.J.; Daminelli, S.; Schroeder, M. Drug Promiscuity in PDB: Protein Binding Site Similarity Is Key, Plos One, 2013, 8(6), e65894.
40. Weill, N.; Rognan D. Alignment-Free Ultra-High-Throughput Comparison of Druggable Protein−Ligand Binding Sites, J. Chem. Inf. Model., 2010, 50(1), 123-135.
41. Berman, H.M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T.N.; Weissig, H.; Shindyalov, I.N.; Bourne, P.E. The Protein Data Bank, Nucleic Acids Res., 2000, 28, 235-242.
42. Liu, T.; Lin, Y.; Wen, X.; Jorrisen, R.N.; Gilson, M.K. Binding DB: a web-accessible database of experimentally determined proteinligand binding affinities, Nucleic Acids Res., 2007, 35, D198-D201
43. Bader, G.D.; Cary, M.P.; Sander, C. Pathguide: a pathway resource list, Nucleic Acids Res., 2006, 34, D504-D506.
44. Gaulton, A.; Bellis, L.J.; Bento, A.P.; Chambers, J.; Davies, M.; Hersey, A.; Light, Y.; McGlinchey, S.; Michalovich, D.; Al-Lazikani, B.; Overington, J.P. ChEMBL: a large-scale bioactivity database for drug discovery, Nucleic Acids Res., 2012, 40, D1100-D1107.
45. Bryant, S. PubChem: an information resource linking chemistry and biology. Abstr. Pap. Am. Chem. S., 2007, 231.
46. Bolton, E.E.; Wang, Y.; Thiessen, P.A.; Bryant, S.H. PubChem: integrated platform of small molecules and biological activities, Annu. Rep. Com. Chem., 2008, 4(12), 217-241.
47. Evans, J.M.; Lopez, E.; Roth, B.L. The NIMH Psychoactive Drug Screening Program’s Ki database: an on-line, searchable database of receptor-ligand affinity values, Soc. Neurosci. Abs., 2001, 27, 2076
48. Bjorling, E.; Uhlen, M. Antibodypedia-a portal for sharing antibody and antigen validation data, Mol. Cell. Proteomics, 2008, 7, 2028-2037.
49. Cottingham, K. Antibodypedia seeks to answer the question: How good is your antibody? J. Proteome Res., 2008; 7(10), 4213-4213.
50. Kiermer V. Antibodypedia-A web portal to share antibody validation data, Nat. Methods, 2008, 5, 860-870.
51. Chambers, J.; Davies, M.; Gaulton, A.; Hersey, A.; Velankar, S.; Petryszak, R.; Hastings, J.; Bellis, L.; McGlinchey, S.; Overington, J.P. UniChem: a unified chemical structure cross-referencing and identifier tracking system, J. Cheminform., 2013, 5(1), 3-11.
52. Chambers, J.; Davies, M.; Gaulton, A.; Papadatos, G.; Hersey, A.; Overington, J.P. UniChem: extension of InChI-based compound mapping to salt, connectivity and stereochemistry layers, J. Cheminform., 2014, 6(1), 43-53.
53. The Binding Database. www.bindingDB.org (Accessed June 03 2015).
54. ChEMBL. www.ebi.ac.uk/chembl/ (Accessed June 03 2015).
55. Pence, H. E.; Williams, A. ChemSpider: An Online Chemical Information Resource, J. Chem. Educ., 2010, 87(11), 1123-1124.
56. ChemSpider. www.chemspider.com (Accessed June 03 2015).
57. Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A.C.; Wishart, D.S. DrugBank 3.0: a comprehensive resource for ‘omics’ research on drugs, Nucleic Acids Res., 2011, 39, D1035-D1041.
58. DrugBank. www.drugbank.ca (Accessed June 03 2015).
59. Li, Q.; Xiang, J.F.; Yang, Q.F.; Sun, H.X.; Guan, A.J.; Tang, Y.L. G4LDB: a database for discovering and studying G-quadruplex ligands, Nucleic Acids Res., 2013, 41(1), D1115-D1123.
60. G-quadruplex ligands database. http://www.g4ldb.org/ci2/index.php (Accessed June 03 2015).
61. Alexander, S.P.; Mathie, A.; Peters, J. A. Guide to Receptors and Channels (GRAC), 5th edition. British J. Pharmacol., 2011, 164(1), S1-S324.
62. Sharman, J.L.; Mpamhanga, C.P.; Spedding, M.; Germain, P.; Staels, B.; Dacquet, C.; Laudet, V.; Harmar, A.J.; Nc, I. IUPHARDB: new receptors and tools for easy searching and visualization of pharmacological data, Nucleic Acids Res., 2011, 39, D534-D538.
63. Harmar, A.J.; Hills, R.A.; Rosser, E.M.; Jones, M.; Buneman, O.P.; Dunbar, D.R.; Greenhill, S.D.; Hale, V.A.; Sharman, J.L.; Bonner, T.I.; Catterall, W.A.; Davenport, A.P.; Delagrange, P.; Dollery, C.T.; Foord, S.M.; Gutman, G.A.; Laudet, V.; Neubig, R.R.; Ohlstein, E.H.; Olsen, R.W.; Peters, J.; Pin, J.P.; Ruffolo, R.R.; Searls, D.B.; Wright, M.W.; Spedding, M. IUPHAR-DB: the IUPHAR database of G protein-coupled receptors and ion channels, Nucleic Acids Res., 2009, 37, D680-D685.
64. IUPHAR BPS. www.guidetopharmacology.org (Accessed June 03 2015).
65. DTP Developmental Therapeutics Program NCI/NIH. http://dtp.nci.nih.gov (Accessed June 03 2015).
66. Wang, R.; Fang, X.; Lu, Y.; Wang, S. The PDBbind database: collection of binding affinities for protein-ligand complexes with known three-dimensional structures, J. Med. Chem., 2004, 47, 2977-2980.
67. Li Y.; Liu Z.H.; Li J.; Han L.; Liu J.; Zhao Z.X.; Wang R.X. Comparative Assessment of Scoring Functions on an Updated Benchmark: I. Compilation of the Test Set, J. Chem. Inf. Model., 2014, 54(6), 1700-1716.
68. Li Y.; Han L.; Liu Z.H.; Wang R.X. Comparative Assessment of Scoring Functions on an Updated Benchmark: II. Evaluation Methods and General Results, J. Chem. Inf. Model., 2014, 54 (6), 1717-1736.
69. PdbBind. www.pdbbind.org.cn (Accessed June 03 2015).
70. PDSP-NIMH Psychoactive Drug Screening Program https://pdspdb.unc.edu/pdspWeb/ (Accessed June 03 2015).
71. Wang, Y.; Xiao, J.; Suzek, T.O.; Zhang, J.; Wang, J.; Zhou, Z.; Han, L.; Karapetyan, K.; Dracheva, S.; Shoemaker, B.A.; Bolton, E.; Gindulyte, A.; Bryant, S.H. PubChem’s BioAssay Database. Nucleic Acids Res., 2012, 40, D400-D412.
72. PubChem. http://pubchem.ncbi.nlm.nih.gov/ (Accessed June 03 2015).
73. Gunther, S.; Kuhn, M.; Dunkel, M.; Campillos, M.; Senger, C.; Petsalaki, E.; Ahmed, J.; Urdiales, E.G.; Gewiess, A.; Jensen, L.J.; Schneider, R.; Skoblo, R.; Russell, R.B.; Bourne, P.E.; Bork, P.; Preissner, R. SuperTarget and Matador: resources for exploring drug-target relationships, Nucleic Acids Res., 2008, 36, D919-D922.
74. Hecker, N.; Ahmed, J.; von Eichborn, J.; Dunkel, M.; Macha, K.; Eckert, A.; Gilson, M.K.; Bourne, P.E.; Preissner, R. SuperTarget goes quantitative: update on drug-target interactions, Nucleic Acids Res., 2012, 40, D1113-D1117.
75. SuperTarget. http://bioinf-apache.charite.de/supertarget_v2/ (Accessed June 03 2015).
76. Qin, C.; Zhang, C.; Zhu, F.; Xu, F.; Chen, S.Y.; Zhang, P.; Li, Y.H.; Yang, S.Y.; Wei, Y.Q.; Tao, L.; Chen, Y.Z. Therapeutic target database update 2014: a resource for targeted therapeutics, Nucleic Acids Res., 2014, 42, D1118-D1123.
77. Therapeutic Target Database (TTD). http://bidd.nus.edu.sg/group/cjttd/ (Accessed June 03 2015).
78. Irwin, J.J.; Sterling, T.; Mysinger, M.M.; Bolstad, E.S.; Coleman, R.G. ZINC: A Free Tool to Discover Chemistry for Biology, J. Chem. Inf. Model., 2012, 52(7),1757-1768.
79. Zinc Database. http://zinc.docking.org/ (Accessed June 03 2015).
80. Berman, H.; Henrick, K.; Nakamura, H.; Markley, J.L. The worldwide Protein Data Bank (wwPDB): ensuring a single, uniform archive of PDB data, Nucleic Acids Res., 2007, 35, D301-D303.
81. Nair, R.; Liu, J.; Soong, T.T.; Acton, T.B.; Everett, J.K.; Kouranov, A.; Fiser, A.; Godzik, A.; Jaroszewski, L.; Orengo, C.; Montelione, G.T.; Rost, B. Structural genomics is the largest contributor of novel structural leverage, J. Struct. Funct. Genomics, 2009, 10, 181-191.
82. Terwilliger, T. C.; Bricogne, G. Continuous mutual improvement of macromolecular structure models in the PDB and of X-ray crystallographic software: the dual role of deposited experimental data, Acta Cryst., 2014, 70, 2533-2543
83. Brown, E.N.; Ramaswamy, S. Quality of protein crystal structures, Acta Cryst., 2007, 63, 941-950.
84. Dalby, A.; Nourse, J.G.; Hounshell, W.D.; Gushurst, A.K.I.; Grier, D.L.; Leland, B.A.; Laufer, J. Description of several chemical structure file formats used by computer programs developed at Molecular Design Limited, J. Chem. Inf. Comp. Sci., 1992, 32, 244-255.
85. Read, R. J.; Adams, P. D.; Arendall, W. B. A new generation of crystallographic validation tools for the Protein Data Bank, Structure, 2011, 19, 1395-1412.
86. Montelione, G. T.; Nilges, M.; Bax, A.; Guntert, P.; Herrmann, T.; Richardson, J.S.; Schwieters, C.D.; Vranken, W.F.; Vuister, G.W.; Wishart, D.S.; Berman, H.M.; Kleywegt, G.J.; Markley, J.L.; Recommendations of the wwPDB NMR Structure Validation Task Force, Structure, 2013, 21, 1563-1570.
87. The Protein Data Bank. http://www.rcsb.org/pdb/home/home.do (Accessed June 03 2015).
88. Paul, N.; Kellenberger, E.; Bret, G.; Muller, P.; Rognan, D. Recovering the true targets of specific ligands by virtual screening of the Protein Data Bank, Proteins, 2004, 54, 671-680
89. Marcou, G.; Rognan, D. Optimizing fragment and scaffold docking by use of molecular interaction fingerprints, J. Chem. Inf. Model., 2007, 47, 195-207.
90. Meslamani, J.; Rognan, D.; Kellenberger, E. sc-PDB: a database for identifying variations and multiplicity of “druggable” binding sites in proteins, Bioinformatics, 2011, 27, 1324-1326.
91. Desaphy, J.; Bret, G.; Rognan, D.; Kellenberger, E. sc-PDB: a 3Ddatabase of ligandable binding sites-10 years on, Nucleic Acids Res., 2015, 43, D399-D404.
92. Duan, J.; Dixon, S.L.; Lowrie, J.F.; Sherman, W. Analysis and Comparison of 2D Fingerprints: Insights into Database Screening Performance Using Eight Fingerprint Methods, J. Molec. Graph. Model., 2010, 29, 157-170.
93. Sastry, M.; Lowrie, J.F.; Dixon, S.L.; Sherman, W. Large-Scale Systematic Analysis of 2D Fingerprint Methods and Parameters to Improve Virtual Screening Enrichments, J. Chem. Inf. Model., 2010, 50, 771-784.
94. Katritzky, A. R.; Karelson, M.; Maran, U.; Wang, Y. QSPR and QSAR Models Derived Using Large Molecular Descriptor Spaces. A Review of CODESSA Applications, Collect. Czech. Chem. Commun., 1999, 64, 1551-1560.
95. Yang, C.; Tarkhov, A.; Marusczyk, J.; Bienfait, B.; Gasteiger, J.; Kleinoeder, T.; Magdziarz, T.; Sacher, O.; Schwab, C.; Schwo bel, J.; Terfloth, L.; Arvidson, K.; Richard, A.M.; Worth, A.P.; Rathman, J.F. A New Publicly Available Chemical Query Language, CSRML, to support Chemotype Representations for Application to Data Mining and Modeling, J. Chem. Inf. Model., 2015, 55(3), 510-528.
96. Mauri A.; Consonni V.; Pavan M.; Todeschini R.; Dragon Software: An easy approach to molecular descriptors calculations, MATCH Commun. Math. Comput. Chem., 2006, 56, 237-248.
97. Sawada, R.; Kotera, M.; Yamanishi, Y. Benchmarking a wide range of chemical descriptors for drug-target interaction prediction using a chemogenomic approach, Mol. Inform., 2014, 33 (11-12), 719-731.
98. ChemAxon Instant. J. Chem., https://www.chemaxon.com/ products/ instant-jchem-suite/instant-jchem/ (Accessed June 03 2015).
99. Varnek, A.; Fourches, D.; Horvath, D.; Klimchuk, O.; Gaudin, C.; Vayer, P.; Solov’ev, C.; Hoonakker, F.; Tetko, I.; Marcou, G. ISIDA-platform for virtual screening based on fragment and pharmacophoric descriptors, Curr. Comput. Aided. Drug. Des., 2008, 4, 191-198.
100. Bochevarov, A.D.; Harder, E.; Hughes, T.F.; Greenwood, J.R.; Braden, D.A.; Philipp, D.M.; Rinaldo, D.; Halls, M.D.; Zhang, J.; Friesner, R.A. Jaguar: A high-performance quantum chemistry software program with strengths in life and materials sciences, Int. J. Quantum Chem., 2013, 113(18), 2110-2142.
101. Wolber, G.; Langer, T. LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters, J. Chem. Inf. Model., 2005, 45(1), 160-169.
102. Wolber, G.; Dornhofer, A.A.; Langer, T. Efficient overlay of small organic molecules using 3D pharmacophores, J. Comput. Aided. Mol. Des., 2007, 20(12), 773-788.
103. Clark, A.M.; Labute, P.; Santavy, M. 2D Structure Depiction, J. Chem. Inf. Model., 2006, 46, 1107-1123.
104. Clark, A.M.; Labute, P. Detection and Assignment of Common Scaffolds in Project Databases of Lead Molecules, J. Med. Chem., 2008, 52, 469-483.
105. Clark, A.M.; Labute, P. SD File Processing with MOE Pipeline Tools, JCCG, 2008.
106. Yap, C.W. PaDEL-descriptor: an open source software to calculate molecular descriptors and fingerprints, J. Comput. Chem., 2011, 32(7), 1466-1474.
107. Dixon, S.L.; Smondyrev, A.M.; Knoll, E.H.; Rao, S.N.; Shaw, D.E.; Friesner, R.A. PHASE: A New Engine for Pharmacophore Perception, 3D QSAR Model Development, and 3D Database Screening. Methodology and Preliminary Results, J. Comput. Aided Mol. Des., 2006, 20, 647-671.
108. Dixon, S.L.; Smondyrev, A.M.; Rao, S.N. PHASE: A Novel Approach to Pharmacophore Modeling and 3D Database Searching, Chem. Biol. Drug Des., 2006, 67, 370-372.
109. Morris, G.M., Huey, R., Lindstrom, W., Sanner, M.F., Belew, R.K., Goodsell, D.S.; Olson, A.J. Autodock4 and AutoDockTools4: automated docking with selective receptor flexibility, J. Comp. Chem., 2009, 16, 2785-2791.
110. Huey, R.; Morris, G.M.; Olson, A.J.; Goodsell, D. S. A Semiempirical Free Energy Force Field with Charge-Based Desolvation, J. Comp.Chem., 2007, 28, 1145-1152.
111. Lang, P.T.; Brozell, S.R.; Mukherjee, S.; Pettersen, E.T.; Meng, E.C.; Thomas, V.; Rizzo, R.C.; Case, D.A.; James, T.L.; Kuntz, I.D. DOCK 6: Combining Techniques to Model RNA-Small Molecule Complexes, RNA, 2009, 15,1219-1230.
112. Graves, A.P.; Shivakumar, D.E.; Boyce, S.E.; Jacobson, M.P.; Case D.A.; Shoichet B.K. Rescoring Docking Hit Lists for Model Cavity Sites: Predictions and Experimental Testing, J. Mol. Biol., 2008, 377, 914-934.
113. Friesner, R.A.; Murphy, R.B.; Repasky, M.P.; Frye, L.L.; Greenwood, J.R.; Halgren, T.A.; Sanschagrin, P.C.; Mainz, D.T. Extra Precision Glide: Docking and Scoring Incorporating a Model of Hydrophobic Enclosure for Protein-Ligand Complexes, J. Med. Chem., 2006, 49, 6177-6196.
114. Halgren, T.A.; Murphy, R.B.; Friesner, R.A.; Beard, H.S.; Frye, L.L.; Pollard, W.T.; Banks, J.L. Glide: A New Approach for Rapid, Accurate Docking and Scoring. 2. Enrichment Factors in Database Screening, J. Med. Chem., 2004, 47, 1750-1759.
115. Friesner, R.A.; Banks, J.L.; Murphy, R.B.; Halgren, T.A.; Klicic, J. J.; Mainz, D.T.; Repasky, M.P.; Knoll, E.H.; Shaw, D.E.; Shelley, M.; Perry, J.K.; Francis, P.; Shenkin, P.S. Glide: A New Approach for Rapid, Accurate Docking and Scoring. 1. Method and Assessment of Docking Accuracy, J. Med. Chem., 2004, 47, 1739-1749.
116. Verdonk, M. L.; Cole, J. C.; Hartshorn, M. J.; Murray, C.W.; Taylor, R. D. Improved protein-ligand docking using GOLD, Proteins, 2003, 52, 609-623.
117. Hartshorn, M. J.; Verdonk, M. L.; Chessari, G.; Brewerton, S. C.; Mooij, W. T. M.; Mortenson, P. N.; Murray, C.W. Diverse, highquality test set for the validation of protein-ligand docking performance, J._Med. Chem., 2007, 50, 726-741.
118. Kirton, S. B.; Murray, C.W.; Verdonk, M. L.; Taylor, R. D. Prediction of binding modes for ligands in the cytochromes P450 and other heme-containing proteins, Proteins, 2005, 58, 836-844.
119. Brewerton, S. C. The use of protein-ligand interaction fingerprints in docking, Curr. Opin. Drug Discov. Devel., 2008, 11(3), 356-64.
120. Soga, S.; Shirai, H.; Kobori, M.; Hirayama, N. Use of Amino Acid Composition to Predict Ligand-Binding Sites, J. Chem. Inf. Model., 2007, 47, 400-406.
121. Das, S.; Kokardekar, A; Breneman C.M. Rapid comparison of protein binding site surfaces with Property Encoded Shape Distributions (PESD), J. Chem. Inf. Model., 2009, 49(12), 2863-2872.
122. Corbeil, C.R.; Williams, C.I.; Labute, P. Variability in Docking Success Rates Due to Dataset Preparation, J. Comp.-Aided Mol. Des., 2012, 26, 775-786.
123. O’Meara, M.J.; Leaver-Fay, A; Tyka, M.D.; Stein, A.; Houlihan, K.; DiMaio, F.; Bradley, P.; Kortemme, T.; Baker, D.; Snoeyink, J.; Kuhlman B. Combined Covalent-Electrostatic Model of Hydrogen Bonding Improves Structure Prediction with Rosetta, J. Chem. Theory Comput., 2015, 11(2), 609-622.
124. Cheng C.Y.; Chou F.C.; Das R. Modeling complex RNA tertiary folds with Rosetta, Methods. Enzymol., 2015, 553, 35-64.
125. Johnson D.K.; Karanicolas J. Selectivity by small-molecule inhibitors of protein interactions can be driven by protein surface fluctuations, PLoS Comput. Biol., 2015, 11(2), e1004081.
126. Halgren, T. Identifying and characterizing binding sites and assessing druggability, J. Chem. Inf. Model., 2009, 49, 377-389.
127. Halgren, T. New method for fast and accurate binding-site identification and analysis, Chem. Biol. Drug Des., 2007, 69, 146-148.
128. Beisken, S.; Meinl, T.; Wiswedel, B.; De Figueiredo, L. F.; Berthold, M.; Steinbeck, C. KNIME-CDK: Workflow-driven Cheminformatics, BMC Bioinformatics, 2013, 14, 257-260.
129. Tiwari, A.; Sekhar, A.K.T. Workflow based framework for life science informatics, Comput. Biol. Chem., 2007, 31(5-6), 305-319.
130. Forman, G.; Scholz, M. Apples-to-Apples in Cross-Validation Studies: Pitfalls in Classifier Performance Measurement, ACM SIGKDD, 2009, 12(1), 49-57.
131. Kornhuber, J.; Terfloth, L.; Bleich S.; Wiltfang J.; Rupprecht R. Molecular properties of psychopharmacological drugs determining non-competitive inhibition of 5-HT3A receptors, Eur. J. Med. Chem., 2009, 44(6), 2667-2672.
132. Monga, M.; Sausville, E.A. Developmental therapeutics program at the NCI: molecular target and drug discovery process, Leukemia, 2002, 16(4), 520-526.
133. Shankavaram, U.T.; Varma, S.; Kane, D.; Sunshine, M.; Chary, K.K.; Reinhold, W.C.; Pommier, Y.; Weinstein, J.N. CellMiner: a relational database and query tool for the NCI-60 cancer cell lines, BMC Genomics, 2009, 10, 277-286.
134. Reinhold, W.C.; Sunshine, M.; Liu, H.; Varma, S.; Kohn, K.W.; Morris, J.; Doroshow, J.; Pommier, Y. CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set, Cancer Res., 2012, 72(14), 3499-3511.
135. Yamanishi, Y.; Kotera, M.; Moriya, Y.; Sawada, R.; Kanehisa, M.; Goto, S. DINIES: drug-target interaction network inference engine based on supervised analysis, Nucl. Acids Res., 2014, 42(1), 39-45.
136. Takarabe M.; Kotera M.; Nishimura Y.; Goto S.; Yamanishi Y. Drug target prediction using adversed event report systems: a pharmacogenomic approach. Bioinformatics, 2012, 28, i611-i618
137. Konc, J.; Janezic, D.; ProBiS-2012: web server and web services for detection of structurally similar binding sites in proteins, Nucleic Acids Res., 2012, 40, 214-221.
138. Kuhn, M.; Szklarczyk, D.; Pletscher-Frankild, S.; Blicher, T.H.; von Mering, C.; Jensen, L.J.; Bork, P. Stitch 4: integration of protein-chemical interactions with user data, Nucl. Acids Res., 2014, 42 (D1), D401-D407.
139. Liu, R.; Singh, N.; Tawa, G.J.; Wallqvist A.; Reifman J. Exploiting large-scale drug-protein interaction information for computational drug repurposing, BMC Bioinformatics, 2014, 15, 210-226.
140. Nickel, J.; Gohlke, B.; Erehman, J.; Banerjee, P.; Rong, W.W.; Goede, A.; Dunkel, M.; Preissner, R. SuperPred: update on drug classification and target prediction, Nucl. Acids Res., 2014, 42(1), 26-31.
141. Gao, Z.; Li, H.; Zhang, H.; Liu, X.; Kang, L.; Luo, X.; Zhu, W.; Chen, K.; Wang X.; Jiang, H. PDTD: a web-accessible protein database for drug target identification, BMC Bioinformatics, 2008, 9,104-110.
142. Li, H.; Gao, Z.; Kang, L.; Zhang, H.; Yang, K.; Yu, K.; Luo, X.; Zhu, W.; Chen, K.; Shen, J.; Wang X.; Jiang, H. TarFisDock: a web server for identifying drug targets with docking approach, Nucl. Acids Res., 2006, 34, 219-224.
143. Cobanoglu, M.C; Oltvai, Z.N.; Taylor, D.L.; Bahar, I. BalestraWeb: efficient online evaluation of drug-target interactions, Bioinformatics, 2015, 31 (1), 131-133.
144. Low, Y.; Gonzalez, J.; Kyrola, A.; Bickson, D.; Guestrin, C.; Hellerstein, J. M. GraphLab: A New Framework for Parallel Machine Learning, the 26th Conference on Uncertainty in Artificial Intelligence, Catalina Island, California, July 8-11, 2010.
145. Kamburo, A.; Stelzl, U.; Lehrach, H.; Herwig, R. The ConsensusPathDB interaction database: 2013 update, Nucl. Acids Res., 2013, 41 (D1): D793-D800
146. Tao, C.; Sun, J; Zheng, W.J.; Chen, J.; Xu, H; Colorectal cancer drug target prediction using ontology-based inference and network analysis, Database (Oxford) 2015, 2015: bav015.
147. Zhong, Y.; Chen, E.Y.; Liu, R.; Chuang, P.Y.; Mallipattu, S.K.; Tan, C.M.; Clark, N.R.; Deng, Y.; Klotman, P.E.; Ma'ayan, A.; He, J.C. Renoprotective effect of combined inhibition of angiotensinconverting enzyme and histone deacetylase, J. Am. Soc. Nephrol., 2013, 24(5), 801-11.
148. Amelio, I.; Gostev, M.; Knight, R.A.; Willis, A.E.; Melino, G.; Antonov A.V.; DRUGSURV: a resource for repositioning of approved and experimental drugs in oncology based on patient survival information, Cell. Death Dis., 2014, 6(5), 1051-1056.
149. Alaimo, S.; Bonnici, V.; Cancemi, D.; Ferro, A.; Giugno, R.; Pulvirenti, A. DT-Web: a web-based application for drug-target interaction and drug combination prediction through domain-tuned network-based inference, BMC Syst Biol., 2015, 9 (3:S4) 1-11.
150. Wong, J.G. STC: Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines. Drug Discov. Today, 2014, 19 (5) 637-644
151. Pacini, C.; Iorio, F.; Goncalves, E.; Iskar, M.; Klabunde, T.; Bork, P.; Saez-Rodriguez, J. DvD: An R/Cytoscape pipeline for drug repurposing using public repositories of gene expression data. Bioinformatics, 2013, 29(1), 132-134.
152. Bolton, E.; King, J.; Morris, D.L. H2-antagonists in the treatment of colon and breast cancer, Semin Cancer Biol., 2000, 10(1), 3-10.
153. Li, F.; Cao, Y.; Han, L.; Cui, X.; Xie, D; Wang, S.; Bo, X. Gene-ExpressionSignature: an R package for discovering functional connections using gene expression signatures, OMICS, 2013, 17(2),116-118.
154. Kim, J.; Yoo, M.; Kang, J.; Tan, A.C. K-Map: connecting kinases with therapeutics for drug repurposing and development, Hum. Genomics, 2013, 7-20.
155. Roy, A.; Skolnick, J. LIGSIFT: an open-source tool for ligand structural alignment and virtual screening, Bioinformatics, 2015, 31(4), 539-544.
156. Carrella, D.; Napolitano, F.; Rispoli, R.; Miglietta, M.; Carissimo, A.; Cutillo, L.; Sirci, F.; Gregoretti, F.; Di Bernardo, D. Mantra 2.0: an online collaborative resource for drug mode of action and repurposing by network analysis, Bioinformatics, 2014, 130 (12), 1787-1788.
157. Iorio, F.; Bosottic, R.; Scacheric, E.; Belcastro, V.; Mithbaokar, P.; Ferriero, R.; Murino, L.; Tagliaferri, R.; Brunetti-Pierria, N.; Isacchic, A.; di Bernard, D. Discovery of drug mode of action and drug repositioning from transcriptional responses, PNAS, 2010. 107 (33), 14621-14626.
158. Setoain, J.; Franch, M.; Martinez, M.; Tabas-Madrid, D.; Sorzano, C. O. S.; Bakker, A.; Gonzalez-Couto, E.; Elvira, J.; Pascual-Montano, A. NFFinder: an online bioinformatics tool for searching similar transcriptomics experiments in the context of drug repositioning, Nucl. Acids Res., 2015, 43(W1), W193-99.
159. Lee, H.S.; Bae, T.; Lee, J.H.; Kim, D.G.; Oh, Y.S.; Jang, Y.; Kim, J.T.; Lee, J.J.; Innocenti, A.; Supuran, C.T.; Chen, L.; Rho, K.; Kim, S. Rational drug repositioning guided by an integrated pharmacological network of protein, disease and drug, BMC Syst. Biol., 2012, 6, 80-90.
160. Lauria, A.; Tutone, M.; Almerico, A. M. “Virtual lock-and-key approach: The in silico revival of Fischer model by means of molecular descriptors”, Eur. J. Med. Chem., 2011, 46(9), 4274-4280.
161. Lauria, A.; Tutone, M.; Barone, G.; Almerico, A. M. Multivariate analysis in the identification of biological targets for designed molecular structures: The BIOTA protocol, Eur. J. Med. Chem., 2014, 75, 106-110.
162. Lauria, A.; Patella, C.; Abbate, I.; Martorana, A.; Almerico, A.M. Lead optimization through VLAK protocol: New annelated pyrrolo-pyrimidine derivatives as antitumor agents, Eur. J. Med. Chem., 2012, 55, 375-383.
163. Lauria, A.; Abbate, I.; Patella, C.; Martorana, A.; Dattolo, G.; Almerico, A.M.; New Annelated Thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidines, with Potent Anticancer Activity, Designed through VLAK Protocol, Eur. J. Med. Chem., 2013, 62, 416-424.
164. Martorana, A.; Gentile, C.; Perricone, U.; Piccionello, A. P.; Bartolotta, R.; Terenzi, A.; Pace, A.; Mingoia, F.; Almerico, A. M.; Lauria, A.; Synthesis, antiproliferative activity, and in silico insights of new 3-benzoylamino-benzo[b]thiophene derivatives, Eur. J. Med. Chem., 2015, 90, 537-546.
165. Craddock, T.J.A.; Harvey, J. M.; Nathanson, L.; Barnes, Z.M.; Klimas, N.G.; Fletcher, M.A.; Broderick, G. Using gene expression signatures to identify novel treatment strategies in gulf war illness, BMC Med. Genomics, 2015, 8, 36-49.